Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 79,317 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 2 Clear all

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: Rasagiline, Placebo; Drug
Lead sponsor: Richard Barohn, MD; Other
Eligibility: 21 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 10
States / cities: Phoenix, Arizona • Irvine, California • San Francisco, California + 7 more

Conditions: Long-COVID, Brain Fog, Cognition, Memory
Interventions: whole food - walnuts; Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metastatic Breast Cancer
Interventions: lapatinib; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 3
States / cities: Kansas City, Kansas • Topeka, Kansas • Kansas City, Missouri

Conditions: Diabetes, Hypoglycemia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 90 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Premature Pubarche
Interventions: sugar pill, Metformin, glucophage; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 4 Years to 10 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Indianapolis, Indiana • Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: High Risk Pregnancy, Bone Marrow
Interventions: Arts Intervention; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Spinal Fusion, Chronic Lower Back Pain
Interventions: Laser Diode Brace, Sham Laser Diode Brace; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: irofulven; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 51
States / cities: Little Rock, Arkansas • Duarte, California • La Jolla, California + 41 more

Conditions: Endometriosis
Interventions: NettleEndo, Sham NettleEndo Device; Device
Lead sponsor: Samphire Group, Inc.; Industry
Eligibility: 22 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Type1diabetes
Interventions: 4T Education and Care; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 21 Years
Enrollment: 316 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Mantle Cell Lymphoma
Interventions: Acalabrutinib, Bortezomib, Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride, Prednisone, Rituximab, Rituximab and Hyaluronidase Human; Drug · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years to 75 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 3
States / cities: New York, New York • Charlotte, North Carolina • Seattle, Washington

Conditions: Atherosclerosis
Interventions: Rosuvastatin 10 mg, Darapladib 160 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 20 Years to 64 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Urea Cycle Disorder
Interventions: RAVICTI; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Day to 2 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 16
States / cities: Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 13 more

Conditions: Anxiety, Memory, Epilepsy
Interventions: CAMERA (Context-Aware Multimodal Ecological Research and Assessment); Other
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Asthma
Interventions: Tofimilast; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 16
States / cities: Encinitas, California • Riverside, California • DeLand, Florida + 13 more

Conditions: Eye Strain
Interventions: Circular light motion, Diagonal light motion, Peripheral light motion, Exercise; Device · Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Fremont, California

Conditions: Leptomeningeal Metastasis, Leptomeningeal Disease, Leptomeningeal Neoplasms, Leptomeningeal Cancer
Interventions: Neurological Assessment; Other
Lead sponsor: University of Zurich; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ependymoma
Interventions: HLA-A2 restricted synthetic tumor antigen, Imiquimod, enzyme-linked immunosorbent assay, flow cytometry, immunohistochemistry staining method, laboratory biomarker analysis; Biological · Drug · Other
Lead sponsor: James Felker; Other
Eligibility: 12 Months to 21 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: vortioxetine 10 mg tablet, vortioxetine 20 mg tablet, Placebo tablet; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 15
States / cities: Beverly Hills, California • Garden Grove, California • National City, California + 11 more

Conditions: Osteosarcoma
Interventions: Azenosertib, Gemcitabine; Drug
Lead sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 12
States / cities: Los Angeles, California • Oakland, California • Santa Monica, California + 9 more

Conditions: Pancreatic Ductal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer
Interventions: Daratumumab, KRAS vaccine, Nivolumab; Drug · Biological
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
Interventions: ATV, DRV, Cobicistat, BR, F/TAF, LPV/r, Third Unboosted Drug, Cobicistat TOS, F/TAF TOS; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 4 Weeks to 17 Years
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 7
States / cities: Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more

Conditions: Chronic Lymphocytic Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
Interventions: LAVA-051, Interleukin 2; Biological
Lead sponsor: Lava Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • New York, New York • Charlotte, North Carolina + 2 more

Conditions: Healthy Participants
Interventions: BMS-986435; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Effect of Daily Walnut Consumption on Memory in Subjects With Long-COVID

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Hypoglycemia in Hospitalized Patients

Metformin for the Treatment of Premature Pubarche in Girls

The Impact of Arts-Based Interventions on Patient Hospital Experience

Photobiomodulation for Lower Back Pain Post Spinal Fusion and Decompression Surgery

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups

Teamwork, Targets, Technology, and Tight Control in Newly Diagnosed Pediatric T1D - 4T Study

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers

A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders

Prediction of Anxiety and Memory State

A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics

Use of Eye Exercises to Improve Vision

Standardized Clinical Assessment of Patients With Leptomeningeal Metastasis

Immunotherapy for Recurrent Ependymomas in Children Using Tumor Antigen Peptides With Imiquimod

Investigating the Effect of Vortioxetine in Adult ADHD Patients

A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma

Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer

Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants